AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 27533265
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no supervised physical therapy)
Trial: 18924018
Drug: Esomeprazole 20
RxNorm normalized name: esomeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esomeprazole 20 mg daily for one week
Trial: 16424704
Drug: High-dose antithrombin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose antithrombin III (30,000 IU intravenously over 4 days)
Trial: 12661672
Drug: Auditory modality
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Auditory modality verification (e.g., BLENDER-loud)
Trial: 12661672
Drug: Same modality
RxNorm normalized name: SAMe
DrugBank: Ademetionine (DB00118)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Same modality verification (e.g., LEAVES-rustling)
Trial: 12661672
Drug: Different modality
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Different modality verification (e.g., CRANBERRIES-tart)
Trial: 17225476
Drug: Zolpidem 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zolpidem 20 mg (Zol-20)
Trial: 17225476
Drug: Zolpidem 10
RxNorm normalized name: zolpidem 10 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zolpidem 10 mg (Zol-10)
Trial: 17225476
Drug: Melatonin 5
RxNorm normalized name: melatonin 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin 5 mg (Mel-5)
Trial: 17225476
Drug: Melatonin 10
RxNorm normalized name: melatonin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin 10 mg (Mel-10)
Trial: 15771635
Drug: Low-dose ERT
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose ERT (CEE 0.3125 mg/day) + SSRI (fluvoxamine 50 mg/day) for 8 weeks
Trial: 15771635
Drug: Low-dose ERT
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose ERT (CEE 0.3125 mg/day) for 8 weeks
Trial: 9690334
Drug: Usual-care antipsychotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual-care antipsychotic medication
Trial: 201958
Drug: Equine conjugated
RxNorm normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Equine conjugated oestrogens tablets (Premarin)
Trial: 23917775
Drug: Synthetic bacterial
RxNorm normalized name: Synthetic camphor
DrugBank: Synthetic camphor (DB14156)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Synthetic bacterial lipoprotein and TLR1/2 agonist Pam(3)CSK(4) (BLP)
Trial: 16807414
Drug: Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose N-acetylcysteine (600 mg IV bolus before angioplasty and 600 mg orally twice daily for 48 hours after angioplasty)
Trial: 16807414
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose N-acetylcysteine (1200 mg IV bolus and 1200 mg orally twice daily for 48 hours after intervention)
Trial: 16807414
Drug: Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose N-acetylcysteine
Trial: 16807414
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose N-acetylcysteine
Trial: 16807414
Drug: Composite endpoint
RxNorm normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Composite endpoint (death, acute renal failure requiring temporary renal-replacement therapy, or need for mechanical ventilation)
Trial: 12681523
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose modafinil (200 mg/day)
Trial: 12681523
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose modafinil (400 mg/day)
Trial: 9243352
Drug: Intravenous selegiline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous selegiline (0.5 mg)
Trial: 9243352
Drug: Oral selegiline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral selegiline (0.5 mg)
Trial: 9243352
Drug: Oral selegiline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral selegiline (1.0 mg)
Trial: 9243352
Drug: Oral selegiline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral selegiline (1.5 mg)
Trial: 9243352
Drug: Oral selegiline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral selegiline (5 mg)
Trial: 8491244
Drug: Dexamethasone 6
RxNorm normalized name: dexamethasone 6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone 6 mg, administered orally once 12 hours before and once 12 hours after surgery
Trial: 2116312
Drug: Meptazinol (loading
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meptazinol (loading dose 50 mg followed by i.v. infusion 0.5 mg.kg‐1.h‐1)
Trial: 2116312
Drug: Morphine (loading
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine (loading dose 5 mg followed by i.v. infusion 0.05 mg.kg‐1.h‐1)
Trial: 24247559
Drug: Bevacizumab +
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab + capecitabine (maintenance therapy)
Trial: 24247559
Drug: Bevacizumab +
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab + XELOX (induction therapy until progression)
Trial: 19583070
Drug: Intravenous dexmedetomidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous dexmedetomidine (loading dose of 1 microg/kg over 10 min and maintenance dose of 0.5 microg/kg/hr)
Trial: 12711925
Drug: Alcohol consumption
RxNorm normalized name: Alcohol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alcohol consumption (exact dosage and duration not specified)
Trial: 10229979
Drug: Sterile sea
RxNorm normalized name: Deep Sea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sterile sea water spray
Trial: 10229979
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (standard treatment without douche)
Trial: 1679517
Drug: beta1-selective blockers
RxNorm normalized name: beta-Arbutin
DrugBank: Arbutin (DB11217)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: beta1-selective blockers
Trial: 1679517
Drug: nonselective beta-blockers
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nonselective beta-blockers
Trial: 7051761
Drug: Sulfaisodimidine 1
RxNorm normalized name: sulfaisodimidine
DrugBank: Sulfaisodimidine (DB13283)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulfaisodimidine 1 g four times daily (Group I)
Trial: 7051761
Drug: Sulfaisodimidine 2
RxNorm normalized name: sulfaisodimidine
DrugBank: Sulfaisodimidine (DB13283)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulfaisodimidine 2 g twice daily (Group II)
Trial: 30455335
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy after severe hypoglycemia
Trial: 23312435
Drug: Maintenance cognitive
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance cognitive therapy (MCT)
Trial: 21261433
Drug: Brief Strategic
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Brief Strategic Family Therapy
Trial: 19697822
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg kg(‐1) rocuronium (group E)
Trial: 19697822
Drug: 0.1 mg
RxNorm normalized name: biotin 0.1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 mg kg(‐1) cis‐atracurium (group N)
Trial: 19697822
Drug: 1.5 mg
RxNorm normalized name: boron 1.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 mg kg(‐1) suxamethonium (group P)
Trial: 9361690
Drug: Pirenzepine (PZP)
RxNorm normalized name: pirenzepine
DrugBank: Pirenzepine (DB00670)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pirenzepine (PZP) 100 mg orally
Trial: 1315100
Drug: Incision plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Incision plus curettage and primary suture under antibiotic (Clindamycin) cover
Trial: 3883264
Drug: Metronidazole 400
RxNorm normalized name: metronidazole 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metronidazole 400 mg administered one hour before and again four and eight hours after abortion
Trial: 29106076
Drug: TXA (1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TXA (1.0 g)
Trial: 18537053
Drug: L-arginine application
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-arginine application
Trial: 17143986
Drug: Cognitive behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioral treatment plus usual care
Trial: 10929922
Drug: Switching to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Switching to loratadine after initial therapy with fexofenadine
Trial: 10929922
Drug: Switching to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Switching to fexofenadine after initial therapy with loratadine
Trial: 3535757
Drug: Fenofibrate (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenofibrate (100 mg three times daily)
Trial: 27184170
Drug: Alirocumab 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alirocumab 50 mg
Trial: 25068344
Drug: Autologous fat
RxNorm normalized name: Hard fat
DrugBank: Hard fat (DB11578)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous fat injection (group A)
Trial: 25068344
Drug: Autologous fat
RxNorm normalized name: Hard fat
DrugBank: Hard fat (DB11578)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous fat injection with plasma rich in growth factors (group B)
Trial: 20087330
Drug: Rosiglitazone (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosiglitazone (4 mg) enema treatment once daily for 14 days
Trial: 20087330
Drug: Mesalazine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mesalazine (1 g) enema treatment once daily for 14 days
Trial: 8192751
Drug: High ratio
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High ratio of immune complex-dissociated to native antibody titer
Trial: 8192751
Drug: Native antibody
RxNorm normalized name: Castanea sative leaf extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Native antibody titers
Trial: 27855365
Drug: RFA (in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RFA (in 8 patients with CEA > 50 ng/mL)
Trial: 27855365
Drug: CIK cell
RxNorm normalized name: Testone CIK KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CIK cell therapy (in 8 patients with CEA > 50 ng/mL)
Trial: 18949289
Drug: Propolis orabase
RxNorm normalized name: ORABASE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propolis orabase gel (PRO)
Trial: 18949289
Drug: Orabase gel
RxNorm normalized name: Orabase Gel-B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orabase gel without active component (Control)
Trial: 10084271
Drug: Latanoprost 0.005%
RxNorm normalized name: LATANOPROST 0.005% SOLN,OPH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Latanoprost 0.005% once daily (add-on therapy to timolol)
Trial: 10084271
Drug: Pilocarpine 2%
RxNorm normalized name: PILOCARPINE 2% SOLN,OPH
DrugBank: Pilocarpine (DB01085)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pilocarpine 2% three times daily (add-on therapy to timolol)
Trial: 10084271
Drug: Latanoprost 0.005%
RxNorm normalized name: LATANOPROST 0.005% SOLN,OPH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Latanoprost 0.005% once daily (switch from timolol)
Trial: 8747987
Drug: High-dose cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose cyclophosphamide (HD-CY) or dose-escalated ifosfamide/mitoxantrone followed by filgrastim (R-metHuG-CSF, 300 micrograms/day)
Trial: 8747987
Drug: Sequential high-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential high-dose treatment
Trial: 1905614
Drug: Etidronate disodium
RxNorm normalized name: Etidronate Disodium
DrugBank: Etidronic acid (DB01077)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Etidronate disodium (Didronel; 750 mg orally daily)
Trial: 31046082
Drug: Pembrolizumab 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab 200 mg administered intravenously every 3 weeks until cancer progression, toxicity, or completion of 2 years (Cohort A)
Trial: 31046082
Drug: Pembrolizumab 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab 200 mg administered intravenously every 3 weeks until cancer progression, toxicity, or completion of 2 years (Cohort B)
Trial: 31046082
Drug: Pembrolizumab 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab 200 mg administered intravenously every 3 weeks until cancer progression, toxicity, or completion of 2 years (Cohort A and B)
Trial: 18640457
Drug: Dimebon (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dimebon (60 mg/day, 20 mg three times a day)
Trial: 12133397
Drug: CEE 0.625
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CEE 0.625 mg + MPA 2 mg + Ca-D 1 tablet daily (Group A)
Trial: 12133397
Drug: CEE 0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CEE 0.3 mg + MPA 2 mg + Ca-D 1 tablet daily (Group B)
Trial: 12133397
Drug: Cal-D 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cal-D 1 tablet daily alone (Group C)
Trial: 10394089
Drug: Intravenous morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous morphine 5 mg (n = 6)
Trial: 10394089
Drug: Naloxone 2.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naloxone 2.4 mg (n = 6)
Trial: 2202773
Drug: Erythromycin Base
RxNorm normalized name: Erythromycin base
DrugBank: Erythromycin (DB00199)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Erythromycin Base Filmtab (nonenteric-coated) at 1 g/d
Trial: 2202773
Drug: Erythromycin Base
RxNorm normalized name: Erythromycin base
DrugBank: Erythromycin (DB00199)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Erythromycin Base Filmtab (nonenteric-coated) at 2 g/d
Trial: 2202773
Drug: Eryc (enteric-coated)
RxNorm normalized name: Erycibe obtusifolia stem extract
DrugBank: Erythromycin (DB00199)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eryc (enteric-coated) at 1 g/d
Trial: 2202773
Drug: Eryc (enteric-coated)
RxNorm normalized name: Erycibe obtusifolia stem extract
DrugBank: Erythromycin (DB00199)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eryc (enteric-coated) at 2 g/d
Trial: 45211
Drug: IV almitrine
RxNorm normalized name: almitrine
DrugBank: Almitrine (DB01430)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV almitrine 0.5 mg/kg
Trial: 26189067
Drug: Investigational group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigational group (oxaliplatin + leucovorin + fluorouracil during adjuvant chemotherapy)
Trial: 26189067
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (fluorouracil + leucovorin during adjuvant chemotherapy)
Trial: 26189067
Drug: Investigational group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigational group (preoperative and postoperative treatment)
Trial: 26189067
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (preoperative and postoperative treatment)
Trial: 15308586
Drug: Tomato oleoresin
RxNorm normalized name: Tomato
DrugBank: Tomato (DB10573)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tomato oleoresin extract (3 capsules daily for 2 weeks, each containing 4.88 mg lycopene, 0.48 mg phytoene, 0.44 mg phytofluene, and 1.181 mg alpha-tocopherol)
Trial: 11160057
Drug: L‐NMMA (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L‐NMMA (10 mg)
Trial: 11160057
Drug: L‐arginine (375
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L‐arginine (375 mg)
Trial: 11160057
Drug: L‐NMMA vs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L‐NMMA vs L‐arginine
Trial: 11160057
Drug: L‐NMMA and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L‐NMMA and L‐arginine
Trial: 9748428
Drug: Fluticasone propionate,
RxNorm normalized name: fluticasone propionate, micronized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluticasone propionate, 1000 microgram administered twice daily at 08:00 h and 20:00 h
Trial: 8046314
Drug: Pirprofen (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pirprofen (400 mg t.i.d.)
Trial: 24905321
Drug: Oxycodone hydrochloride
RxNorm normalized name: Oxycodone Hydrochloride
DrugBank: Oxycodone (DB00497)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oxycodone hydrochloride 2.5 mg
Trial: 24905321
Drug: Oxycodone hydrochloride
RxNorm normalized name: Oxycodone Hydrochloride
DrugBank: Oxycodone (DB00497)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oxycodone hydrochloride 5 mg
Trial: 24905321
Drug: Oxycodone hydrochloride
RxNorm normalized name: Oxycodone Hydrochloride
DrugBank: Oxycodone (DB00497)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oxycodone hydrochloride 10 mg
Trial: 24905321
Drug: Oxycodone hydrochloride
RxNorm normalized name: Oxycodone Hydrochloride
DrugBank: Oxycodone (DB00497)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oxycodone hydrochloride (all doses)
Trial: 23536652
Drug: Ribavirin monotherapy
RxNorm normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ribavirin monotherapy for 6 weeks
Trial: 12668582
Drug: Oral linezolid
RxNorm normalized name: Linezolid
DrugBank: Linezolid (DB00601)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral linezolid (375, 500, or 625 mg)
Trial: 12668582
Drug: Intravenous linezolid
RxNorm normalized name: Linezolid
DrugBank: Linezolid (DB00601)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous linezolid (500 or 625 mg)
Trial: 1671434
Drug: Carbamazepine or
RxNorm normalized name: carbamazepine Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbamazepine or phenobarbitone treatment
Trial: 6306348
Drug: Chemotherapy and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy and radiation therapy (Cytoxan, CCNU, methotrexate + radiation to brain, chest, and abdomen)
Trial: 6306348
Drug: Chemotherapy alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy alone (Cytoxan, CCNU, methotrexate)
Trial: 6306348
Drug: Partial response
RxNorm normalized name: rosin partially dimerized glycerol ester
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Partial response to therapy
Trial: 29178317
Drug: Client‐driven, customized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Client‐driven, customized self‐management program with up to 3 in‐home visits from a registered nurse or registered dietitian, a monthly group wellness program, monthly provider team case conferences, and care coordination and system navigation.
Trial: 26739392
Drug: High hs‐TnT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High hs‐TnT level (≥14 ng/l) in diabetic group
Trial: 21290836
Drug: Medication (antihistamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication (antihistamine and anti-HP infection)
Trial: 21290836
Drug: Medication combined
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication combined with acupoint catgut embedding therapy
Trial: 17890862
Drug: ivabradine 5
RxNorm normalized name: ivabradine 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ivabradine 5 mg b.i.d.
Trial: 17890862
Drug: ivabradine 7.5
RxNorm normalized name: ivabradine 7.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ivabradine 7.5 mg b.i.d.
Trial: 11549982
Drug: Salmeterol xinafoate
RxNorm normalized name: Salmeterol Xinafoate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salmeterol xinafoate 42 mcg via metered dose inhaler twice daily
Trial: 9613227
Drug: General light
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General light (G)
Trial: 7640145
Drug: Oral sumatriptan
RxNorm normalized name: Sumatriptan
DrugBank: Sumatriptan (DB00669)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral sumatriptan 200 mg
Trial: 1107359
Drug: Intramuscular nefopam
RxNorm normalized name: nefopam
DrugBank: Nefopam (DB12293)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular nefopam HCl 20 mg
Trial: 1107359
Drug: Intramuscular pethidine
RxNorm normalized name: pethidine
DrugBank: Meperidine (DB00454)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intramuscular pethidine 50 mg
Trial: 1107359
Drug: Oral nefopam
RxNorm normalized name: nefopam
DrugBank: Nefopam (DB12293)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral nefopam HCl 60 mg t.i.d. for three days
Trial: 1107359
Drug: Oral placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral placebo t.i.d. for three days
Trial: 20575304
Drug: Sizhi‐Xifang treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sizhi‐Xifang treatment in the treatment group (24 cases) after incision healing
Trial: 20575304
Drug: Minimal invasive
RxNorm normalized name: Centipeda minima whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minimal invasive percutaneous plate treatment in the control group
Trial: 19048106
Drug: Amnioreduction (drainage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amnioreduction (drainage of 2000 ml fluid, range 700‐3500 ml)
Trial: 11818767
Drug: Clonidine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clonidine (10 microg x kg(‐1) administered over 5 min + 5 microg x kg(‐1) x h(‐1) intravenous) given before mu-opioid receptor blockade